Department of Neurosciences, Moores Cancer Center, Translational Neuro-Oncology Laboratories, 3855 Health Sciences Dr. #0819, UC San Diego, La Jolla, CA, USA.
Expert Rev Anticancer Ther. 2013 Nov;13(11):1297-305. doi: 10.1586/14737140.2013.851160. Epub 2013 Oct 21.
Despite recent scientific advances in the understanding of the biology of malignant gliomas, there has been little change in the overall survival for this devastating disease. New and innovative treatments are under constant investigation. Starting in the 1990s, there was an interest in using viral therapeutics for the treatment of malignant gliomas. Multiple strategies were pursued, including oncolytic viral therapy, enzyme/pro-drug combinations and gene transfer with viral vectors. Multiple Phase I and II trials demonstrated the safety of these techniques, but clinically showed limited efficacy. However, this led to a better understanding of the pitfalls of viral therapy and encouraged the development of new approaches and improved delivery methods. Here we review the prior and ongoing clinical trials of viral therapy for gliomas, and discuss how novel strategies are currently being utilized in clinical trials.
尽管近年来在恶性脑胶质瘤生物学方面取得了科学进展，但这种毁灭性疾病的总体生存率仍没有明显变化。新的创新治疗方法正在不断研究中。从上世纪 90 年代开始，人们对使用病毒疗法治疗恶性脑胶质瘤产生了兴趣。人们探索了多种策略，包括溶瘤病毒治疗、酶/前药联合治疗和基因转移的病毒载体。多项 I 期和 II 期临床试验证明了这些技术的安全性，但临床疗效有限。然而，这导致人们更好地了解病毒治疗的缺陷，并鼓励开发新的方法和改进的递送方法。本文回顾了病毒治疗脑胶质瘤的既往和正在进行的临床试验，并讨论了目前在临床试验中如何利用新的策略。
